Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 20/20 | 0.61 |
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4726545 | 1.00 | PPARD (0.61) | PPARDPPARAPPARG | |
| SCHEMBL4730648 | 0.93 | PPARD (0.59) | PPARDPPARAPPARG | |
| SCHEMBL4730148 | 0.92 | PPARD (0.56) | PPARDPPARAPPARG | |
| SCHEMBL16468780 | 0.92 | PPARD (0.53) | PPARDPPARAPPARG | |
| SCHEMBL15543948 | 0.92 | PPARD (0.53) | PPARDPPARAPPARG | |
| SCHEMBL16468516 | 0.91 | PPARD (0.53) | PPARDPPARAPPARG | |
| SCHEMBL15543171 | 0.91 | PPARD (0.51) | PPARDPPARAPPARG | |
| SCHEMBL15543623 | 0.91 | PPARD (0.51) | PPARDPPARAPPARG | |
| SCHEMBL16468515 | 0.91 | PPARD (0.53) | PPARDPPARAPPARG | |
| SCHEMBL4784245 | 0.88 | PPARD (0.59) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008035359-A2 | OXIMINOPHENOXYALKANOIC ACID AND PHENYLALKANOIC ACID DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2008-03-27 | — | — | WO | claimed |
| EP-2864309-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | Cadila Healthcare Limited (IN) | 2015-04-29 | — | — | EP | disclosed |
| US-20150051144-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LTD (IN) | 2015-02-19 | — | — | US | disclosed |
| WO-2014002105-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | CADILA HEALTHCARE LIMITED (IN) | 2014-01-03 | — | — | WO | disclosed |
| WO-2008035359-A2 | OXIMINOPHENOXYALKANOIC ACID AND PHENYLALKANOIC ACID DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051144-A1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER DISEASES | PCSK9, HMGCR, CETP | PPARD 214/4885PPARA 192/4885PPARG 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.